These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 19596945

  • 1. Side-effects of pre-operative epirubicin-paclitaxel therapy in primary breast cancer associated with tumor biology.
    Warm M, Kates R, Thomas A, Fischer T, Harbeck N.
    Anticancer Res; 2009 Jul; 29(7):2675-80. PubMed ID: 19596945
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [Neoadjuvant chemotherapy for primary breast cancer].
    Li JF, Ouyang T, Wang TF, Lin BY.
    Zhonghua Zhong Liu Za Zhi; 2004 Aug; 26(8):493-5. PubMed ID: 15555342
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Optimized pro-active management of anemia by Epoetin alpha in pre-operative chemotherapy for primary breast cancer.
    Warm M, Kates R, Dick M, Thomas A, Mallmann P, Hoopmann M, Harbeck N.
    Oncol Rep; 2009 Mar; 21(3):777-85. PubMed ID: 19212639
    [Abstract] [Full Text] [Related]

  • 7. Cytotoxic and antiproliferative activity of the single agent epirubicin versus epirubicin plus tamoxifen as primary chemotherapy in human breast cancer: a single-institution phase III trial.
    Bottini A, Berruti A, Brizzi MP, Bersiga A, Generali D, Allevi G, Aguggini S, Bolsi G, Bonardi S, Tondelli B, Vana F, Tampellini M, Alquati P, Dogliotti L.
    Endocr Relat Cancer; 2005 Jun; 12(2):383-92. PubMed ID: 15947110
    [Abstract] [Full Text] [Related]

  • 8. [Clinicopathological evaluation of preoperative chemotherapy with doxorubicin plus cyclophosphamide followed by paclitaxel for locally advanced breast cancer].
    Miyake T, Miyahara S, Fujii K, Taniguchi M, Yamamura K, Tadokoro K, Tanimura M, Nakamura H.
    Gan To Kagaku Ryoho; 2009 Mar; 36(3):401-5. PubMed ID: 19295263
    [Abstract] [Full Text] [Related]

  • 9. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers.
    Tanei T, Morimoto K, Shimazu K, Kim SJ, Tanji Y, Taguchi T, Tamaki Y, Noguchi S.
    Clin Cancer Res; 2009 Jun 15; 15(12):4234-41. PubMed ID: 19509181
    [Abstract] [Full Text] [Related]

  • 10. Good response to paclitaxel predicts high rates of pathologic complete response for breast cancer patients treated preoperatively with paclitaxel followed by 5-fluorouracil, epirubicin and cyclophosphamide.
    Kim SJ, Taguchi T, Shimazu K, Tanji Y, Tamaki Y, Noguchi S.
    Oncology; 2009 Jun 15; 77(2):134-9. PubMed ID: 19628951
    [Abstract] [Full Text] [Related]

  • 11. Clinical and pathological response to primary chemotherapy in patients with locally advanced breast cancer grouped according to hormonal receptors, Her2 status, grading and Ki-67 proliferation index.
    Miglietta L, Vanella P, Canobbio L, Parodi MA, Guglielmini P, Boccardo F.
    Anticancer Res; 2009 May 15; 29(5):1621-5. PubMed ID: 19443376
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
    Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, Campone M, Kubista E, Greil R, Bianchi G, Steinseifer J, Molloy B, Tokaji E, Gardner H, Phillips P, Stumm M, Lane HA, Dixon JM, Jonat W, Rugo HS.
    J Clin Oncol; 2009 Jun 01; 27(16):2630-7. PubMed ID: 19380449
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Safety and efficacy of weekly paclitaxel followed by FEC100 as primary systemic therapy for breast cancer].
    Naito K, Oura S, Yoshimasu T, Tamaki T, Ohta F, Nakamura R, Shimizu Y, Kiyoi M, Hirai Y, Miyasaka M, Okamura Y.
    Gan To Kagaku Ryoho; 2009 Feb 01; 36(2):251-4. PubMed ID: 19223740
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Adjuvant dose-dense sequential chemotherapy with epirubicin, CMF and weekly paclitaxel in patients with resected high-risk breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study.
    Papadimitriou CA, Papakostas P, Timotheadou E, Aravantinos G, Bamias A, Fountzilas G.
    Cancer Invest; 2008 Jun 01; 26(5):491-8. PubMed ID: 18568771
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.